3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase NA
1
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Lymphoma
7
Lymphoma, Follicular
6
Leukemia, Biphenotypic, Acute
6
Leukemia
6
Lymphoma, Non-Hodgkin
4
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, Large-Cell, Immunoblastic
3
Leukemia, Myeloid, Acute
3
Burkitt Lymphoma
3
Prostatic Neoplasms
2
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Multiple Myeloma
2
Lymphohistiocytosis, Hemophagocytic
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Graft vs Host Disease
2
Epstein-Barr Virus Infections
2
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Pneumonia, Pneumocystis
1
Pneumonia
1
Pain
1
Neurotoxicity Syndromes
1
Neuroma, Acoustic
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Lymphoma, Large-Cell, Anaplastic
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Leukemia, Myeloid, Chronic-Phase
1
Interventions
Olanzapine
4
Cyclophosphamide
4
Voriconazole
3
Tranexamic Acid
3
Standard of Care
3
nilotinib
2
letermovir
2
fludarabine phosphate
2
Zoledronic Acid
2
Whole-Body Irradiation
2
Practice Guidelines as Topic
2
Peripheral Blood Stem Cell Transplantation
2
Mycophenolic Acid
2
Methods
2
Imatinib Mesylate
2
Educational Status
2
Early Intervention, Educational
2
Doxorubicin
2
Cyclosporins
2
Cyclosporine
2
venetoclax
1
trihexyltetradecylphosphonium chloride
1
thymoglobulin
1
shengxuening
1
posaconazole
1
pembrolizumab
1
olaparib
1
maribavir
1
lenvatinib
1
ferrous succinate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Hematologic Neoplasms
×
Methylprednisolone
×
Clear all
NCT02944045
2020-10-06
PIC
Assistance Publique - Hôpitaux de Paris
Phase 3
Unknown
222 enrolled